PLUS THERAPEUTICS INC PSTV 深 滬
已收盤 02-06 16:00:00 美东时间
0.2599
+0.026
+11.12%
華盛通- 最 高0.2599
- 今 開0.23
- 成交量 848.48万股
- 最 低 0.2223
- 昨 收 0.2339
- 總市值 4635.87万
- 52周最高 2.3099
- 市盈率 靜 --
- 換手率 4.76%
- 52周最低 0.1634
- 委 比 -28.82%
- 總股本 1.78亿
- 歷史最高 343.35
- 量 比 0.89
- 振 幅 16.08%
- 歷史最低 0.1634
- 每 手 1
- 風險率 0.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
U.S. RESEARCH ROUNDUP-Applied Materials, Procter & Gamble, RLI
U.S. RESEARCH ROUNDUP-Applied Materials, Procter & Gamble, RLI Jan 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Materials, Procter & Gamble and RLI, on Friday. HIGHLIGHTS * Applied Materials Inc AMAT.O : Be
01-23 15:13
D. Boral Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $4
D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lowers the price target from $5 to $4.
01-22 20:41
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
Plus Therapeutics provides a business update, highlighting progress in its REYOBIQ clinical trials and CNSide commercialization. The company aims to scale CNSide and prepare for pivotal trials, supported by a $15 million offering. Key 2026 milestones include optimizing REYOBIQ dosing, completing trials for glioblastoma and pediatric brain cancer, expanding commercial coverage, and launching additional CNS tumor tests.
01-22 12:45
BRIEF-Plus Therapeutics To Provide Business Update On Thursday
BRIEF-Plus Therapeutics To Provide Business Update On Thursday Jan 21 (Reuters) - Plus Therapeutics Inc PSTV.O : PLUS THERAPEUTICS TO PROVIDE BUSINESS UPDATE AND HOST CONFERENCE CALL ON THURSDAY, JANUARY 22, 2026 AT 9:00 A.M. ET Source text: ID:nGNXbhKMkd Further company coverage: PSTV.O (( Reuters.
01-22 06:02
Benzinga Bulls And Bears: TSMC, Rocket Lab, J.B. Hunt — And Space Stocks Soar
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
01-17 21:21
Plus Therapeutics Prices $15M Public Offering Of 39.5M Units At $0.38 Each
Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announcesthe
01-14 21:03
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Plus Therapeutics Completes Type B Meeting With FDA Over Next Steps On REYOBIQ Pivotal Study Strategy For Leptomeningeal Metastases
Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers,
01-08 20:35
